Prostate Cancer clinical trials in Delaware

7 actively recruiting prostate cancer trials at 6 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology

NCT ID: NCT05946213

Sites in Delaware:

Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Wilmington Hospital — Wilmington, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology

NCT ID: NCT04134260

Sites in Delaware:

Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware
Beebe Health Campus — Rehoboth Beach, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06931340

Sites in Delaware:

Bayhealth Hospital Kent Campus — Dover, Delaware
Bayhealth Hospital Sussex Campus — Milford, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca

NCT ID: NCT06120491

Sites in Delaware:

Research Site — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc

NCT ID: NCT04585750

Sites in Delaware:

Medical Oncology Hematology Consultants — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis

NCT ID: NCT05176483

Sites in Delaware:

Exelixis Clinical Site #49 — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc

NCT ID: NCT04485013

Sites in Delaware:

Christiana Care Helen F. Graham Cancer Center — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20